Skip to main content

Table 1 Summary of demographic and clinical parameters of SSc patients

From: Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity

Mean age ± standard deviation (years)

58 ± 11

Sex (F/M)

16/2

Mean Disease duration (years)

9.7 ± 6.9

Anti-Scl70 (n = %)

10 (55.5%)

CENP-A and CENP-B (n = %)

8 (44.5%)

ILD at CTscan (Yes/No)

11 (61.1%) / 7 (38.9%)

Skin involvement (lcSSc / dcSSc)

14 (77.7%) / 4 (22.3%)

NVC patterns (E/A/L)

2 (11.1%) / 10 (55.5%) / 6 (33.4%)

Therapy

No immunosuppressor = 7 (38.9%)

MMF = 7 (38.9%)

MTX = 2 (11.1%)

Cyclosporine = 2 (11.1%)

Endothelin receptor antagonists = 8 (44.4%)

  1. Demographic and clinical parameters of enrolled SSc patients. Data include the age, female and male (F/M) ratio, skin involvement, nailfold videocapillaroscopy pattern of microan giopathy and auto-antibody profile. Data are expressed as means ± standard deviations (SD) or numbers (percentages of the total population). lcSSc “limited” cutaneous skin involve ment, dcSSc “diffuse” cutaneous skin involvement, NVC nailfold videocapillaroscopy, E “Early” NVC pattern of microangiopathy, A “Active” NVC pattern of microangiopathy, L “Late” NVC pattern of microangiopathy, CENP anti-centromere antibodies, Scl70 anti-topoisomerase-I antibodies, MMF mycophenolate mofetil, MTX methotrexate